You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

XIIDRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xiidra, and when can generic versions of Xiidra launch?

Xiidra is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-four patent family members in twenty-five countries.

The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xiidra

A generic version of XIIDRA was approved as lifitegrast by MICRO LABS on August 4th, 2023.

  Try a Trial

Drug patent expirations by year for XIIDRA
Drug Prices for XIIDRA

See drug prices for XIIDRA

Recent Clinical Trials for XIIDRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
State University of New York College of OptometryPhase 4
Novartis PharmaceuticalsPhase 4
Bucci Laser Vision InstitutePhase 4

See all XIIDRA clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for XIIDRA
Paragraph IV (Patent) Challenges for XIIDRA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XIIDRA Ophthalmic Solution lifitegrast 5% 208073 4 2020-07-13

US Patents and Regulatory Information for XIIDRA

XIIDRA is protected by sixteen US patents.

Patents protecting XIIDRA

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for treatment of eye disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Compositions and methods for treatment of eye disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Compositions and methods for treatment of eye disorders
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

LFA-1 inhibitor and methods of preparation and polymorph thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Modulators of cellular adhesion
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Crystalline pharmaceutical and methods of preparation and use thereof
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XIIDRA

When does loss-of-exclusivity occur for XIIDRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08317473
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 02984
Estimated Expiration: ⤷  Try a Trial

Patent: 58665
Estimated Expiration: ⤷  Try a Trial

Patent: 05972
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1873797
Estimated Expiration: ⤷  Try a Trial

Patent: 2056485
Estimated Expiration: ⤷  Try a Trial

Patent: 2065694
Estimated Expiration: ⤷  Try a Trial

Patent: 2065893
Estimated Expiration: ⤷  Try a Trial

Patent: 5943534
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 09371
Estimated Expiration: ⤷  Try a Trial

Patent: 65124
Estimated Expiration: ⤷  Try a Trial

Patent: 65125
Estimated Expiration: ⤷  Try a Trial

Patent: 76508
Estimated Expiration: ⤷  Try a Trial

Patent: 67886
Estimated Expiration: ⤷  Try a Trial

Patent: 32444
Estimated Expiration: ⤷  Try a Trial

Patent: 97775
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 08037
Estimated Expiration: ⤷  Try a Trial

Patent: 11500683
Estimated Expiration: ⤷  Try a Trial

Patent: 11516607
Estimated Expiration: ⤷  Try a Trial

Patent: 11518155
Estimated Expiration: ⤷  Try a Trial

Patent: 11521896
Estimated Expiration: ⤷  Try a Trial

Patent: 14132032
Estimated Expiration: ⤷  Try a Trial

Patent: 14132033
Estimated Expiration: ⤷  Try a Trial

Patent: 14133751
Estimated Expiration: ⤷  Try a Trial

Patent: 14221808
Estimated Expiration: ⤷  Try a Trial

Patent: 16128515
Estimated Expiration: ⤷  Try a Trial

Patent: 16153432
Estimated Expiration: ⤷  Try a Trial

Patent: 17141310
Estimated Expiration: ⤷  Try a Trial

Patent: 18127485
Estimated Expiration: ⤷  Try a Trial

Patent: 20023546
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 10004281
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 30406
Estimated Expiration: ⤷  Try a Trial

Patent: 63703
Estimated Expiration: ⤷  Try a Trial

Patent: 30024
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XIIDRA around the world.

Country Patent Number Title Estimated Expiration
Australia 2017265071 LFA-1 inhibitor and polymorph thereof ⤷  Try a Trial
Australia 2004287875 ⤷  Try a Trial
Brazil 112015014367 formulações inibidoras de lfa-1 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XIIDRA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2444079 C02444079/01 Switzerland ⤷  Try a Trial FORMER OWNER: SARCODE BIOSCIENCE INC., US
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.